Page 31 - Haematologica July

Immune TTP: interplay between haplotypes & environment
(TTP-HUS) Registry: A Community Perspective of Patients with Clinically Diagnosed TTP-HUS. Semin Hematol. 2004;41(1):60-67.
72. Martino S, Jamme M, Deligny C, et al. Thrombotic thrombocytopenic purpura in Black people: Impact of ethnicity on survival and genetic risk factors. PLoS One. 2016;11(7):3-12.
73. Cataland SR, Yang S Bin, Witkoff L, et al. Demographic and ADAMTS13 biomarker data as predictors of early recurrences of idiopathic thrombotic thrombocytopenic purpura. Eur J Haematol. 2009;83(6):559- 564.
74. Sheikh N, Sharma S. Impact of ethnicity on cardiac adaptation to exercise. Nat Rev Cardiol. 2014;11(4):198-217.
75. Hughes GC, Choubey D. Modulation of autoimmune rheumatic diseases by oestro- gen and progesterone. Nat Rev Rheumatol. 2014;10(12):740-751.
76. Diamanti-Kandarakis E, Bergiele A. The influence of obesity on hyperandrogenism and infertility in the female. Obes Rev. 2001;2(4):231-238.
77. Lombardi AM, Fabris R, Scarda A, et al. Presence of anti-ADAMTS13 antibodies in obesity. Eur J Clin Invest. 2012;42(11):1197- 1204.
78. Sadler JE. Pathophysiology of thrombotic thrombocytopenic purpura. Blood. 2017;130 (10):1181-1188.
79. Terrell DR, Motto DG, Kremer Hovinga JA, Lammle B, George JN, Vesely SK. Blood group O and black race are independent risk factors for thrombotic thrombocytopenic purpura associated with severe ADAMTS13 deficiency. Transfusion. 2011;51(10):2237- 2243.
80. Muia J, Zhu J, Gupta G, et al. Allosteric acti- vation of ADAMTS13 by von Willebrand factor. Proc Natl Acad Sci USA. 2014;111(52):18584-18589.
81. South K, Luken BM, Crawley JTB, et al. Conformational activation of ADAMTS13. Proc Natl Acad Sci USA. 2014;111(52): 18578-18583.
82. Deforche L, Roose E, Vandenbulcke A, et al. Linker regions and flexibility around the metalloprotease domain account for confor- mational activation of ADAMTS-13. J Thromb Haemost. 2015;13(11):2063-2075.
83. Gao W, Anderson PJ, Sadler JE. Extensive contacts between ADAMTS13 exosites and von Willebrand factor domain A2 con- tribute to substrate specificity. Blood. 2008;112(5):1713-1719.
84. Jian C, Xiao J, Gong L, et al. Gain-of-func- tion ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombo- cytopenic purpura. Blood. 2012;119 (16):3836-3843.
85. Roose E, Schelpe AS, Joly BS, et al. An open conformation of ADAMTS13 is a hallmark of acute acquired thrombotic thrombocy- topenic purpura. J Thromb Haemost. 2018;16(2):378-388.
86. Morgand M, Buffet M, Busson M, et al. High prevalence of infectious events in thrombot- ic thrombocytopenic purpura and genetic relationship with toll-like receptor 9 poly- morphisms: experience of the French Thrombotic Microangiopathies Reference Center. Transfusion. 2014;54(2):389-397.
87. Fuchs TA, Kremer Hovinga JA, Schatzberg D, Wagner DD, Lammle B. Circulating DNA and myeloperoxidase indicate disease activ- ity in patients with thrombotic microan- giopathies. Blood. 2012;120(6):1157-1164.
88. Pillai VG, Bao J, Zander CB, et al. Human neutrophil peptides inhibit cleavage of von Willebrand factor by ADAMTS13: a poten- tial link of inflammation to TTP. Blood. 2016;128(1):110-119.
89. Motto DG, Chauhan AK, Zhu G, et al. Shigatoxin triggers thrombotic thrombocy- topenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest. 2005;115(10):2752-2761.
90. Verbij FC, Fijnheer R, Voorberg J, Sorvillo N. Acquired TTP: ADAMTS13 meets the immune system. Blood Rev. 2014;28(6):227- 234.
91. Sorvillo N, Van Haren SD, Kaijen PH, et al.
Preferential HLA-DRB1*11–dependent pres- entation of CUB2-derived peptides by ADAMTS13-pulsed dendritic cells. Blood. 2013;121(17):3502-3510.
92. Tersteeg C, Verhenne S, Roose E, et al. ADAMTS13 and anti-ADAMTS13 autoan- tibodies in thrombotic thrombocytopenic purpura – current perspectives and new treatment strategies. Expert Rev Hematol. 2016;9(2):209-221.
93. Chapin J, Weksler B, Magro C, Laurence J. Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura. Br J Haematol. 2012;157(6):772- 774.
94. Feng S, Kroll MH, Nolasco L, Moake J, Afshar-Kharghan V. Complement activation in thrombotic microangiopathies. Br J Haematol. 2013;160(3):404-406.
95. Osafo-Addo AD, Koram KA, Oduro AR, Wilson M, Hodgson A, Rogers WO. HLA- DRB1*04 allele is associated with severe malaria in Northern Ghana. Am J Trop Med Hyg. 2008;78(2):251-255.
96. Tong X, Chen L, Liu S, et al. Polymorphisms in HLA-DRB1 gene and the risk of tubercu- losis: a meta-analysis of 31 studies. Lung. 2015;193(2):309-318.
97. Mancini I, Ricaño-Ponce I, Pappalardo E, et al. Immunochip analysis identifies novel susceptibility loci in the human leukocyte antigen region for acquired thrombotic thrombocytopenic purpura. J Thromb Haemost. 2016;14(12):2356-2367.
98. Liu GY, Fairchild PJ, Smith RM, Prowle JR, Kioussis D, Wraith DC. Low avidity recog- nition of self-antigen by T cells permits escape from central tolerance. Immunity. 1995;3(4):407-415.
99. James EA, Kwok WW. Low-affinity major histocompatibility complex-binding pep- tides in type 1 diabetes. Diabetes. 2008;57(7):1788-1789.
100. South K, Freitas MO, Lane DA. A model for the conformational activation of the struc- turally quiescent metalloprotease ADAMTS13 by von willebrand factor. J Biol Chem. 2017;292(14):5760-5769.
haematologica | 2018; 103(7)
1109